Low-density lipoprotein cholesterol reduction with evolocumab and its use in clinical practice: evidence from swedish national register data

26 August 2022 (08:00 - 19:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Professor Maria Svensson

Uppsala University Hospital, Uppsala (Sweden)

4 More presentations in this session

Presentation thumbnail

PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease

Doctor D. Kannenkeril (Erlangen, DE)

Abstract Slides Video

Presentation thumbnail

Impact of alirocumab added to high-intensity statin therapy on platelet function in AMI patients: a pre-specified substudy of the randomized, placebo-controlled PACMAN-AMI trial

Doctor L. Raber (Bern, CH)

Abstract Slides Video

Presentation thumbnail

Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry

Professor K. Ray (London, GB)

Abstract Slides Video

Presentation thumbnail

High individual variability in LDL-reductions after inclisiran administration in a "real-world setting"

Professor O. Weingaertner (Jena, DE)

Abstract Slides Video

Access the full session

Session thumbnail

Lipid-lowering by PCSK9 modulation: what’s new?

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

You may be interested in

Congress Presentation

Breaking through: CETP inhibitors and the future of lipid therapy

Congress Presentation

Case 1 - recurrent acute coronary syndrome in a patient with familial hypercholesterolaemia and high lipoprotein(a): the Turkish perspective

Congress Presentation

What’s new on lipid-lowering drugs: from statins to gene editing and beyond

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources